ECB-ART-52457
Cancers (Basel)
2023 Jul 27;1515:. doi: 10.3390/cancers15153824.
Show Gene links
Show Anatomy links
Extraintestinal Cancers in Inflammatory Bowel Disease: A Literature Review.
Massano A
,
Bertin L
,
Zingone F
,
Buda A
,
Visaggi P
,
Bertani L
,
de Bortoli N
,
Fassan M
,
Scarpa M
,
Ruffolo C
,
Angriman I
,
Bezzio C
,
Casini V
,
Ribaldone DG
,
Savarino EV
,
Barberio B
.
???displayArticle.abstract???
BACKGROUND: Inflammatory bowel disease (IBD) is a group of chronic multifactorial inflammatory disorders including two major entities: Crohn's disease (CD) and ulcerative colitis (UC). Preliminary evidence suggests that patients with IBD may be at increased risk of developing intestinal and extraintestinal cancers (EICs). Actually, little is known about the association between IBD and EICs, and there is ever-growing concern regarding the safety of immunomodulators and biological therapy, which may represent a risk factor for carcinogenesis. AIMS: The aim of this review is to summarize the evidence regarding the association between IBD and EICs, the safety of immunomodulators and biological therapy and the management of immunomodulators and biologic agents in IBD patients with prior or current EICs. RESULTS: IBD patients have a higher risk of developing different forms of extraintestinal solid organ tumors and hematological malignancies. Immunomodulators and biological therapy may increase the risk of developing some types of EICs and may be consciously used in patients with IBD and current or prior history of malignancy. CONCLUSIONS: Decisions regarding the use of immunomodulators or biological therapies should be made on an individual basis, considering a multidisciplinary approach involving oncologists.
???displayArticle.pubmedLink??? 37568640
???displayArticle.link??? Cancers (Basel)
References [+] :
Abbas,
Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort.
2014, Pubmed
Abbas, Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort. 2014, Pubmed
Abreu, Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension. 2022, Pubmed
Actis, History of Inflammatory Bowel Diseases. 2019, Pubmed
Alayo, Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease. 2022, Pubmed
Algaba, Incidence, management, and course of cancer in patients with inflammatory bowel disease. 2015, Pubmed
Algaba, Risk of cancer, with special reference to extra-intestinal malignancies, in patients with inflammatory bowel disease. 2013, Pubmed
Allegretti, Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia/cancer? A meta-analysis. 2015, Pubmed
Anderson, Risks of myeloid malignancies in patients with autoimmune conditions. 2009, Pubmed
Ariyaratnam, Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis. 2014, Pubmed
Armstrong, Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. 2010, Pubmed
Askling, Risk of haematopoietic cancer in patients with inflammatory bowel disease. 2005, Pubmed
Axelrad, Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. 2016, Pubmed
Axelrad, Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents. 2016, Pubmed
Bangolo, Association between Multiple Myeloma and Ulcerative Colitis: A Cross-Sectional Analysis. 2023, Pubmed
Barberio, Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. 2021, Pubmed
Beaugerie, Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. 2009, Pubmed
Beaugerie, Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. 2014, Pubmed
Beaugerie, Management of inflammatory bowel disease patients with a cancer history. 2014, Pubmed
Beigel, Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. 2014, Pubmed
Berinstein, Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature. 2023, Pubmed
Bernstein, Cancer risk in patients with inflammatory bowel disease: a population-based study. 2001, Pubmed
Bezzio, Cancer Risk in Patients Treated with the JAK Inhibitor Tofacitinib: Systematic Review and Meta-Analysis. 2023, Pubmed
Bhatia, Abnormalities of uterine cervix in women with inflammatory bowel disease. 2006, Pubmed
Biancone, Cancer and immunomodulators in inflammatory bowel diseases. 2015, Pubmed
Biancone, Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. 2011, Pubmed
Biank, Association of Crohn's disease, thiopurines, and primary epstein-barr virus infection with hemophagocytic lymphohistiocytosis. 2011, Pubmed
Bonovas, Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. 2016, Pubmed
Borren, Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. 2019, Pubmed
Bourrier, Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. 2016, Pubmed
Brambilla, Hemophagocytic Lymphohistiocytosis and Inflammatory Bowel Disease: Case Report and Systematic Review. 2020, Pubmed
Brito-Zerón, Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies. 2016, Pubmed
Burgevin, Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study. 2022, Pubmed
Burns, Inflammatory Bowel Disease and the Risk of Prostate Cancer. 2019, Pubmed
Card, Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data. 2020, Pubmed
Casas-Deza, Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry. 2023, Pubmed
Caspi, The association of inflammatory bowel disease and leukemia--coincidence or not? 1995, Pubmed
Caviglia, Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease. 2021, Pubmed
Chang, Intestinal and Extraintestinal Cancers Associated With Inflammatory Bowel Disease. 2018, Pubmed
Chaparro, Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry. 2017, Pubmed
Chaparro, Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry. 2021, Pubmed
Cheddani, Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study. 2016, Pubmed
Chupin, Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease. 2020, Pubmed
Cohen, The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. 2020, Pubmed
Colombel, Infliximab, azathioprine, or combination therapy for Crohn's disease. 2010, Pubmed
Cottone, Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. 2011, Pubmed
Curtis, Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data. 2021, Pubmed
D'Haens, Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy. 2017, Pubmed
Dahiya, Safety and Effectiveness of Vedolizumab in Elderly Patients with Inflammatory Bowel Disease: A Systematic Review & Meta-Analysis. 2023, Pubmed
Danese, Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. 2022, Pubmed
Deepak, T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. 2013, Pubmed
Dugué, Risk of cervical cancer in women with autoimmune diseases, in relation with their use of immunosuppressants and screening: population-based cohort study. 2015, Pubmed
DʼHaens, Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry. 2018, Pubmed
Ekbom, Extracolonic malignancies in inflammatory bowel disease. 1991, Pubmed
Erichsen, Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease: a national cohort study, 1978-2003. 2009, Pubmed
Esse, Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis. 2020, Pubmed
Everhov, Inflammatory bowel disease and pancreatic cancer: a Scandinavian register-based cohort study 1969-2017. 2020, Pubmed
Feagan, Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. 2023, Pubmed
Festa, Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. 2022, Pubmed
Fidder, Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. 2009, Pubmed
Fraser, Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. 2002, Pubmed
GBD 2017 Inflammatory Bowel Disease Collaborators, The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. 2020, Pubmed
Garg, Risk of cancer in inflammatory bowel disease: going up, going down, or still the same? 2016, Pubmed
Giordani, Myocarditis and inflammatory bowel diseases: A single-center experience and a systematic literature review. 2023, Pubmed
Goetgebuer, Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study. 2021, Pubmed
Gordon, ECCO Guidelines on Inflammatory Bowel Disease and Malignancies. 2023, Pubmed
Greenstein, Extraintestinal cancers in inflammatory bowel disease. 1985, Pubmed
Greuter, Malignancies in Inflammatory Bowel Disease. 2020, Pubmed
Guerra, Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry Study. 2023, Pubmed
Gómez-García, Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain. 2013, Pubmed
Hagen, Nonmelanoma Skin Cancer Risk in Patients With Inflammatory Bowel Disease Undergoing Thiopurine Therapy: A Systematic Review of the Literature. 2018, Pubmed
Hasan, Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancy. 2022, Pubmed
Hazenberg, Neoplasia and Precursor Lesions of the Female Genital Tract in IBD: Epidemiology, Role of Immunosuppressants, and Clinical Implications. 2018, Pubmed
Hemminki, Cancer risks in ulcerative colitis patients. 2008, Pubmed
Hemminki, Cancer risks in Crohn disease patients. 2009, Pubmed
Herrinton, Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. 2011, Pubmed
Hibi, Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial. 2023, Pubmed
Ho, Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008). 2009, Pubmed
Holmer, Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study. 2023, Pubmed
Holubar, Primary intestinal lymphoma in patients with inflammatory bowel disease: a descriptive series from the prebiologic therapy era. 2011, Pubmed
Hong, Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy. 2022, Pubmed
Hovde, Malignancies in Patients with Inflammatory Bowel Disease: Results from 20 Years of Follow-up in the IBSEN Study. 2017, Pubmed
Huai, Inflammatory bowel disease and risk of cholangiocarcinoma: evidence from a meta-analysis of population-based studies. 2014, Pubmed
Huang, Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: A systematic review and meta-analysis. 2019, Pubmed
Huang, Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China. 2023, Pubmed
Jess, Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. 2004, Pubmed
Jess, Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. 2013, Pubmed
Jung, Cancer Risk in the Early Stages of Inflammatory Bowel Disease in Korean Patients: A Nationwide Population-based Study. 2017, Pubmed
Jussila, Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland. 2013, Pubmed
Kandiel, Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. 2005, Pubmed
Kappelman, Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. 2014, Pubmed
Karlén, Increased risk of cancer in ulcerative colitis: a population-based cohort study. 1999, Pubmed
Karmiris, Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. 2009, Pubmed
Kaser, Inflammatory bowel disease. 2010, Pubmed
Khan, Incidence of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Patients With Inflammatory Bowel Disease and the Impact of Thiopurines on Their Risk. 2021, Pubmed
Khan, Repeated Occurrences of Basal Cell Cancer in Patients With Inflammatory Bowel Disease Treated With Immunosuppressive Medications. 2020, Pubmed
Khanna, Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. 2015, Pubmed
Kim, Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. 2015, Pubmed
Kirchgesner, Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. 2018, Pubmed
Kobayashi, Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis. 2020, Pubmed
Kopylov, Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologics: A Quebec Claims Database Study. 2015, Pubmed
Kotlyar, Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. 2015, Pubmed
Kotlyar, A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. 2011, Pubmed
Laredo, Risk of Cancer in Patients with Inflammatory Bowel Diseases and Keys for Patient Management. 2023, Pubmed
Lees, Lack of association between cervical dysplasia and IBD: a large case-control study. 2009, Pubmed
Lees, The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. 2009, Pubmed
Lemaitre, Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. 2017, Pubmed
Levhar, Propagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease. 2020, Pubmed
Lewis, Inflammatory bowel disease is not associated with an increased risk of lymphoma. 2001, Pubmed
Li, Features of patients with inflammatory bowel diseases who develop hemophagocytic lymphohistiocytosis. 2016, Pubmed
Lichtenstein, Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience. 2018, Pubmed
Lichtenstein, Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry. 2014, Pubmed
Lichtenstein, Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program. 2023, Pubmed
Lin, Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study. 2023, Pubmed
Ljung, Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. 2004, Pubmed
Lo, The Risk of Extraintestinal Cancer in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis of Population-based Cohort Studies. 2021, Pubmed
Loftus, Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. 2023, Pubmed
Long, Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. 2012, Pubmed
Loo, Risk of Malignant Cancers in Inflammatory Bowel Disease. 2019, Pubmed
Macaluso, Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. 2022, Pubmed
Macaluso, Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology. 2023, Pubmed
Macaluso, Effectiveness and Safety of Vedolizumab in Inflammatory Bowel Disease: A Comprehensive Meta-analysis of Observational Studies. 2023, Pubmed
Madanchi, Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience. 2016, Pubmed
Magro, Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). 2014, Pubmed
Mahmoud, Hemophagocytic lymphohistiocytosis in inflammatory bowel disease: a nationwide analysis. 2023, Pubmed
Mala, Solid extraintestinal malignancies in patients with inflammatory bowel disease. 2021, Pubmed
Mann, Risk of Cervical Cancer in Inflammatory Bowel Disease: A Meta-Analysis of Population-Based Studies. 2022, Pubmed
Marabotto, Colorectal Cancer in Inflammatory Bowel Diseases: Epidemiology and Prevention: A Review. 2022, Pubmed
Masunaga, Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. 2007, Pubmed
McAuliffe, Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database. 2015, Pubmed
Mease, Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. 2018, Pubmed
Mellemkjaer, Cancer in patients with ulcerative colitis. 1995, Pubmed
Mir Madjlessi, Inflammatory bowel disease and leukemia. A report of seven cases of leukemia in ulcerative colitis and Crohn's disease and review of the literature. 1986, Pubmed
Mosher, Incidence of Colorectal Cancer and Extracolonic Cancers in Veteran Patients With Inflammatory Bowel Disease. 2018, Pubmed
Muller, Characteristics of Lymphoma in Patients with Inflammatory Bowel Disease: A Systematic Review. 2021, Pubmed
Muller, TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review. 2021, Pubmed
Narous, Risks of Melanoma and Nonmelanoma Skin Cancers Pre- and Post-Inflammatory Bowel Disease Diagnosis. 2023, Pubmed
Nyboe Andersen, Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. 2014, Pubmed
Offman, Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. 2004, Pubmed
Ogawa, Adenocarcinoma associated with perianal fistulas in Crohn's disease. 2013, Pubmed
Olivera, Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis. 2020, Pubmed
Olén, Increasing Risk of Lymphoma Over Time in Crohn's Disease but Not in Ulcerative Colitis: A Scandinavian Cohort Study. 2023, Pubmed
Osterman, Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. 2014, Pubmed
Palli, Hodgkin's disease risk is increased in patients with ulcerative colitis. 2000, Pubmed
Panaccione, Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. 2014, Pubmed
Panés, Five-year Safety Data From OPUS, a European Observational Safety Registry for Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] or Conventional Therapy. 2019, Pubmed
Pasternak, Use of azathioprine and the risk of cancer in inflammatory bowel disease. 2013, Pubmed
Pedersen, Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. 2010, Pubmed
Persson, Crohn's disease and cancer: a population-based cohort study. 1994, Pubmed
Peyrin-Biroulet, I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease. 2023, Pubmed
Peyrin-Biroulet, Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. 2011, Pubmed
Phillips, Diagnosis and Outcome of Extranodal Primary Intestinal Lymphoma in Inflammatory Bowel Disease: An ECCO CONFER Case Series. 2022, Pubmed
Piovani, Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease. 2020, Pubmed
Polesie, Use of methotrexate and risk of skin cancer: a nationwide case-control study. 2023, Pubmed
Poullenot, Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy. 2016, Pubmed
Poullenot, Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study. 2022, Pubmed
Raine, ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. 2022, Pubmed
Ressing, Data analysis of epidemiological studies: part 11 of a series on evaluation of scientific publications. 2010, Pubmed
Rezazadeh Ardabili, Classic drugs in the time of new drugs: real-world, long-term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease. 2022, Pubmed
Ribaldone, Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis. 2019, Pubmed
Rungoe, Inflammatory bowel disease and cervical neoplasia: a population-based nationwide cohort study. 2015, Pubmed
Russo, Incidence of lymphomas in inflammatory bowel disease: report of an emblematic case, systematic review, and meta-analysis. 2023, Pubmed
Sandborn, Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. 2021, Pubmed
Sandborn, Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. 2022, Pubmed
Sandborn, Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. 2012, Pubmed
Sandborn, Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. 2017, Pubmed
Sandborn, Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. 2022, Pubmed
Sandborn, Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. 2019, Pubmed
Sandborn, Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. 2016, Pubmed
Sands, Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. 2007, Pubmed
Sawchik, Randomized clinical trials and observational studies in the assessment of drug safety. 2018, Pubmed
Scharl, Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors-Results from the Swiss IBD Cohort Study. 2019, Pubmed
Scott, Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. 2016, Pubmed
Severyns, Prognosis of Lymphoma in Patients With Known Inflammatory Bowel Disease: A French Multicentre Cohort Study. 2020, Pubmed
Shelton, Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. 2016, Pubmed
Shepherd, Primary malignant lymphoma of the large intestine complicating chronic inflammatory bowel disease. 1989, Pubmed
Siegel, Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. 2009, Pubmed
Sifuentes, Monitoring for Extra-Intestinal Cancers in IBD. 2015, Pubmed
Singh, Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. 2009, Pubmed
Singh, Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. 2011, Pubmed
Singh, Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases. 2022, Pubmed
So, Cancer Risk in 2621 Chinese Patients with Inflammatory Bowel Disease: A Population-based Cohort Study. 2017, Pubmed
Sokol, Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. 2012, Pubmed
Sultan, Prognosis of lymphoma in patients following treatment with 6-mercaptopurine/azathioprine for inflammatory bowel disease. 2012, Pubmed
Taborelli, Risk of intestinal and extra-intestinal cancers in patients with inflammatory bowel diseases: A population-based cohort study in northeastern Italy. 2020, Pubmed
Tassone, Risk factors for malignancy and serious infection in patients with inflammatory bowel disease: a retrospective analysis. 2023, Pubmed
Torres, ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. 2020, Pubmed
Trivedi, Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age. 2020, Pubmed
Vedamurthy, Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study. 2022, Pubmed
Vermeire, Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. 2021, Pubmed
Vermeire, Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. 2017, Pubmed
Wadhwa, Crohn's Disease Is Associated with the Risk for Thyroid Cancer. 2016, Pubmed
Wang, The Incidence Rate and Risk Factors of Malignancy in Elderly-Onset Inflammatory Bowel Disease: A Chinese Cohort Study From 1998 to 2020. 2021, Pubmed
Wang, Associations of Inflammatory Bowel Disease and Subsequent Cancers in a Population-Based Study of Older Adults in the United States. 2022, Pubmed
Wang, Higher Risk for Hematological Malignancies in Inflammatory Bowel Disease: A Nationwide Population-based Study in Taiwan. 2016, Pubmed
Wilson, A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease. 2016, Pubmed
Winther, Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. 2004, Pubmed
Yadav, Effect of Medications on Risk of Cancer in Patients With Inflammatory Bowel Diseases: A Population-Based Cohort Study from Olmsted County, Minnesota. 2015, Pubmed
Yang, Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-tumour Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis. 2018, Pubmed
Ytterberg, Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. 2022, Pubmed
Yu, Risk of malignant lymphomas in patients with inflammatory bowel disease: a population-based cohort study. 2023, Pubmed
Yuan, Autoimmune conditions and pancreatic cancer risk in older American adults. 2023, Pubmed
Zanelli, EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 1). 2021, Pubmed
Zhou, Association between inflammatory bowel disease and risk of incident prostate cancer: a systematic review and meta-analysis of cohort studies. 2023, Pubmed
Zurba, Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review. 2023, Pubmed
de Francisco, Impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease. 2018, Pubmed
de Souza, Immunopathogenesis of IBD: current state of the art. 2016, Pubmed
de Vries, Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands. 2008, Pubmed
van den Heuvel, Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population-based IBDSL cohort. 2016, Pubmed
van der Heijde, Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. 2018, Pubmed